Clinical observation of paclitaxel and cisplatin protocol for treatment patients with advanced or metastatic squamous-cell carcinoma of the esophagus(ESCC)
10.3760/cma.j.issn.1008-6706.2012.11.021
- VernacularTitle:紫杉醇联合顺铂治疗晚期食管鳞癌临床观察
- Author:
Dongping WU
;
Jianguo ZHAO
;
Wanli YE
;
Xiaoyan WANG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Carcinoma,squamous cell;
Chemotherapy;
Paclitaxel;
Cisplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(11):1642-1644,后插2
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of paclitaxel plus cisplatin combination in treatment patients with advanced or metastatic squamous-cell carcinoma of the esophagus(ESCC).Methods Twenty-five patients with advanced or metastatic ESCC received paclitaxel 175mg/m2 by 3-hour infusion on day 1 and cisplatin 25mg/m2 by infusion on day 1 ～ 3.3 weeks as one cycle.Results Twenty-four patients were eligible to be evaluated the efficacy and safety.The overall response rate was 45.8％ with complete and partial response rates of 4.1％ and 41.7％,respectively.The median survival time of all patients was 11 months(95％ CI:8.35 ～ 13.65 months).There was significant difference in the median overall survival between the patients who had showed response versus those who had not(P =0.022).Median survival was 12.5 months(95％ CI:9.11 ～ 15.90 months) and 8 months(95％CI:5.50 -9.50 months),respectively.The 1-year survival probability was 37.3％.The most common toxicities were leukopenia,neutropenia,thrombocytopenia and alopecia.Conclusion The effect of paclitaxel and cisplatin which seems beneficial as first-line therapy in advanced squamous-cell carcinoma of the esophagus had a high effective rate with acceptable toxicity.
